The CHAMP phase 3 study shows strong safety and efficacy of NVK002 for the treatment of myopia.
Houman Hemmati, MD, PhD
Advertisement
Articles by Houman Hemmati, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
The CHAMP phase 3 study shows strong safety and efficacy of NVK002 for the treatment of myopia.
.png "Optometry Times"){kind=logo}
